Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.

Visit the Open Targets Platform which integrates public domain data to enable target identification and prioritisation, or the Open Targets Genetics Portal which identifies targets based on GWAS and functional genomics. We complement data integration with large scale systematic experimental approaches to support target identification, prioritisation and validation. Check out our latest papers describing our experimental target identification approaches in oncology, neurodegeneration, and immunity and inflammation.


News and Events

Open Targets releases new version of the Genetics Portal with FinnGen data

30 June 2021

In our latest Genetics Portal release, we have integrated over 2,700 study endpoints from FinnGen, a public-private collaboration to identify genotype-phenotype correlations in the Finnish population. We have also integrated over 11,800 new studies from GWAS Catalog.

To learn more about our latest release, check out our version 5 (21.06) release blog post.

Our Partners

At the heart of Open Targets is a consortium of complementary partner institutions that bring their respective expertise to collaborative projects that improve how we systematically identify and prioritise drug targets.


Our Principles

A systematic approach

Systematically identify and prioritise the best targets to safely and effectively treat rare and common diseases

Rapid publication

We are committed to rapid publication and making data, methods and results publicly available as soon as possible

Open collaboration

We believe in non-exclusive partnerships that foster the free exchange of ideas, expertise, and data


Follow Us


Summer School: A Crash Course in Open Targets, Part 2

Clare West

22 July 2021

Clare West guides you through the data available in the Open Targets informatics tools, with particular focus on the Genetics Portal.

The PROTACtable genome: a systematic assessment of drug target tractability

Helena Cornu

21 July 2021

An Open Targets project has created a framework to assess whether human proteins could be targeted using Proteolysis Targeting Chimeras (PROTACs).

Summer School: A Crash Course in Open Targets, Part 1

Clare West

15 July 2021

Clare West guides you through how to access data from the Open Targets Platform and Genetics Portal using the web interface and GraphQL API

Open Targets Genetics: Version 5 is out!

Open Targets Outreach

30 June 2021

Open Targets Platform 21.06 has been released!

Open Targets Outreach

30 June 2021

Building the Open Targets Platform Interface using React

Alfredo Miranda

3 June 2021

The Open Targets Platform's user interface uses React and JavaScript to present the data produced by the ETL and served through the API.

Presenting Open Targets to the World via Play, Elasticsearch, Clickhouse and GraphQL

Cinzia Malangone, Jarrod Baker

27 May 2021

The next-generation Platform involved a switch from REST to a GraphQL API. Here we discuss the technology used, including Elasticsearch and Clickhouse.

Wheat from the chaff: extracting, transforming, and loading data for Open Targets

Jarrod Baker, Cinzia Malangone

20 May 2021

The Open Targets Platform features a new ETL pipeline, written in Scala and Spark. Here we detail the purpose of the pipeline, and the technology it is based on.

Towards a reproducible ETL: an overview of Open Targets' platform inputs

Cinzia Malangone, Jarrod Baker

13 May 2021

A discussion of how Platform Input support ensures reproducible inputs for our Extract-Transform-Load (ETL) pipeline.

Beyond associations: building therapeutic hypotheses with Open Targets

Ian Dunham, David Hulcoop

6 May 2021

Open Targets directors describe the elements of a full therapeutic hypothesis, and how Open Targets is working to enable the systematic assessment of such hypotheses.

The next-generation Open Targets Platform: rebuilt, redesigned, reimagined

Helena Cornu

29 April 2021

The next-gen Platform presents an improved user experience. It has been rebuilt with leading-edge technologies including Scala, Spark, and React, and includes new features and data.

How we improved our experimental data curation during the COVID-19 lockdown

Panos Zalmas

22 April 2021

Thanks to the expertise of our lab-based research colleagues, we made valuable contributions to our target validation projects in neurodegeneration and immunology & immflammation.

Q&A with Babatomiwa Adebiyi, an intern with the Open Targets Platform

Helena Cornu, David Ochoa

16 April 2021

Babatomiwa Adebiyi is a computer science student at MIT. He tell us about his machine learning project to prioritise targets in our main therapeutic areas: cancer, immune diseases, and neurological diseases

Job seeking during the pandemic: a Q&A with Kostas Tsirigos

Kostas Tsirigos

26 March 2021

How do you prepare for a virtual interview? What is the remote onboarding process like? Open Targets project manager Kostas Tsirigos tells us about his experience.

Open Targets hosts Kiran Musunuru: insights into the genetic basis of coronary heart disease

Helena Cornu

16 March 2021

An insight into Kiran Musunuru's career, from identifying mutations in ANGPTL3 that protect against heart disease, to working on a "vaccination" against heart attacks, and more.

Sharing is caring: why we need more freely available cancer GWAS summary statistics

Annalisa Buniello

11 March 2021

Though progress has been made to integrate summary statistics into the GWAS Catalog, we make the case for increasing the submission rate for GWAS studies in cancer cohorts.

Getting a finer view on genes leading to Alzheimer’s disease risk

Helena Cornu, Jeremy Schwartzentruber

5 March 2021

New research from Open Targets identifies new genetic regions associated with Alzheimer's disease by integrating multiple layers of omics data.

Rewriting the Open Targets Platform's Drug Index

Jarrod Baker

2 March 2021

The Open Targets Platform maintains an index of molecules with drug-like properties. We discuss of the development of that dataset.

How Open Targets is investigating 100 chromatin-related disorders | Rare Disease Day 2021

Sebastian Gerety

28 February 2021

Neurodevelopmental disorders are rare, but a project led by Sebastian Gerety is illuminating their molecular mechanisms by studying many rare diseases at once.

The Beta version of the next-generation Open Targets Platform has been released!

Helena Cornu

26 February 2021

The new Platform beta reinvents the best of the old Platform with a redesigned experience and improved usability.